On September 17, 2019, the combination therapy of Eisai’s LENVIMA (lenvatinib) and Merck’s KEYTRUDA (pembrolizumab) for the treatment of advanced endometrial carcinoma received simultaneous approvals by Health Canada, the...more
11/8/2019
/ Australia ,
Canada ,
Collaboration ,
Combination Products ,
Drug Approvals ,
Food and Drug Administration (FDA) ,
Health Canada ,
International Relations ,
Multinationals ,
Pharmaceutical Industry ,
Popular ,
Project Orbis
On August 8, 2019, the Court of Queen’s Bench of Alberta dismissed Allergan’s application for judicial review of a decision by the Alberta Minister of Health (the Minister) to designate Allergan’s glaucoma treatment product...more